Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma

Table 4 Cox univariate and multivariate regression analysis of prognostic factors and TMED9 expression for overall survival (OS) in 182 hepatocellular carcinoma (HCC) patients

Variables	Comparison	HR (95% CI)	P value
Cox Univariate Analysis (OS)
Age	< 61 years; ≥ 61 years	1.233 (0.836–1.818)	0.292
Gender	Female; male	0.695 (0.397–1.218)	0.204
Stage	I; II; III	1.255 (0.951–1.657)	0.109
AFP	< 400 ng/mL; ≥ 400 ng/mL	1.398 (0.887–2.203)	0.149
HBV	Negative; positive	1.111 (0.763–1.617)	0.584
HCV	Negative; positive	0.917 (0.603–1.396)	0.687
Tumor size	≤ 5 cm; > 5 cm	1.543 (1.061–2.244)	0.023*
Cut margin	< 1 cm; > 1 cm	0.728 (0.488–1.086)	0.120
PVI	No; yes	3.463 (1.993–6.014)	0.000***
HVI	No; yes	3.971 (1.980–7.964)	0.000***
TMED9	Low; high	1.463 (1.005–2.128)	0.047*
Cox Multivariate Analysis (OS)
Tumor size	≤ 5 cm; > 5 cm	1.323 (0.883–1.981)	0.175
PVI	No; yes	2.444 (1.216–4.911)	0.012*
HVI	No; yes	1.580 (0.656–3.809)	0.308
TMED9	Low; high	1.249 (0.831–1.876)	0.285

HR hazard ratio, CI confidence interval, AFP alpha fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, PVI portal venin invasion, HVI hepatic vein invasion
*p < 0.05, **p < 0.01, ***p < 0.001

ISSN: 1423-0127